Analyst firms · Morgan Stanley · MMM
Morgan Stanley MMM price target and rating history
3M Company (MMM) · Health Care
Morgan Stanley rates 3M Company (MMM) Equal-Weight with a $160 price target, as of its latest action on Oct 22, 2025. It has published 9 rating actions on MMM since July 2021, including 2 upgrades and 1 downgrade. Across 4 firms with a MMM price target in the last 12 months, the median target is $184.
- Current rating
- Equal-Weight
- Price target
- $160
- Median target, all firms
- $184
- Actions on MMM
- 9
Morgan Stanley price target on MMM
Every Morgan Stanley rating on MMM
- Oct 22, 2025
- Sep 6, 2024
- Aug 31, 2023
- Jul 27, 2022
- Feb 17, 2022
- Jan 14, 2022
- Oct 27, 2021
- Oct 7, 2021
- Jul 28, 2021
How other firms rate MMM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Peer Perform | Nov 12, 2026 | |
| Wells Fargo | Equal Weight | $195 | Sep 25, 2026 |
| Bernstein | Mkt Perform | $171 | Sep 25, 2026 |
| Goldman Sachs | Buy | $190 | Jun 15, 2026 |
| Deutsche Bank | Hold | $178 | Dec 8, 2025 |
Questions about Morgan Stanley and MMM
- What is Morgan Stanley's price target for MMM?
- Morgan Stanley's latest stated price target for 3M Company (MMM) is $160, from its action on Oct 22, 2025.
- What is Morgan Stanley's rating on MMM?
- Morgan Stanley rates MMM Equal-Weight, a neutral rating, as of Oct 22, 2025.
- When did Morgan Stanley last change its view on MMM?
- On Oct 22, 2025, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $160.
- How does Morgan Stanley's MMM target compare with other analysts?
- Across 4 firms with a MMM price target in the last 12 months, the median target is $184.
More MMM rating histories
- Wolfe Research4
- Wells Fargo7
- Bernstein4
- Deutsche Bank10
- UBS4
- RBC Capital Markets7
- Barclays8
- Citigroup3
- Credit Suisse7
- Mizuho3
All Morgan Stanley ratingsMMM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.